hengrui glp-1 Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial Investors put $400M into biotech

FDA Approved Indications Type 2 Diabetes (Mounjaro): Approved for use as an adjunct to diet and exercise to improve glycemic control

Continue Resistance Training Resistance training remains one of the most important tools for preserving muscle mass and maintaining mechanical loading during weight loss

Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione

The FDA typically restricts compounded versions once branded supply returns to normal levels

Packaging performance is verified through ISTA-certified testing to confirm it holds up under realistic shipping stressors

is again adding to its GLP-1 arsenal, this time via a $2 billion licensing and collaboration agreement with Yaopharma, a subsidiary of Chinas Fosun Pharmaceutical Co